340 related articles for article (PubMed ID: 12466002)
1. Etoricoxib.
Cochrane DJ; Jarvis B; Keating GM
Drugs; 2002; 62(18):2637-51; discussion 2652-3. PubMed ID: 12466002
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Patrignani P; Capone ML; Tacconelli S
Expert Opin Pharmacother; 2003 Feb; 4(2):265-84. PubMed ID: 12562317
[TBL] [Abstract][Full Text] [Related]
3. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
4. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
5. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Matheson AJ; Figgitt DP
Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
[TBL] [Abstract][Full Text] [Related]
7. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study.
Malmstrom K; Sapre A; Couglin H; Agrawal NG; Mazenko RS; Fricke JR
Clin Ther; 2004 May; 26(5):667-79. PubMed ID: 15220011
[TBL] [Abstract][Full Text] [Related]
8. [Etoricoxib (Arcoxia)].
Leclercq P; Malaise MG
Rev Med Liege; 2004 May; 59(5):345-9. PubMed ID: 15270001
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model.
Malmstrom K; Kotey P; Coughlin H; Desjardins PJ
Clin J Pain; 2004; 20(3):147-55. PubMed ID: 15100590
[TBL] [Abstract][Full Text] [Related]
10. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Hunt RH; Harper S; Callegari P; Yu C; Quan H; Evans J; James C; Bowen B; Rashid F
Aliment Pharmacol Ther; 2003 Jan; 17(2):201-10. PubMed ID: 12534404
[TBL] [Abstract][Full Text] [Related]
11. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
[TBL] [Abstract][Full Text] [Related]
12. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Hochberg MC
Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
[TBL] [Abstract][Full Text] [Related]
13. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
Fenton C; Keating GM; Wagstaff AJ
Drugs; 2004; 64(11):1231-61. PubMed ID: 15161329
[TBL] [Abstract][Full Text] [Related]
14. Etoricoxib.
Matsumoto AK; Cavanaugh PF
Drugs Today (Barc); 2004 May; 40(5):395-414. PubMed ID: 15319795
[TBL] [Abstract][Full Text] [Related]
15. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
Riendeau D; Percival MD; Brideau C; Charleson S; Dubé D; Ethier D; Falgueyret JP; Friesen RW; Gordon R; Greig G; Guay J; Mancini J; Ouellet M; Wong E; Xu L; Boyce S; Visco D; Girard Y; Prasit P; Zamboni R; Rodger IW; Gresser M; Ford-Hutchinson AW; Young RN; Chan CC
J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.
Birbara CA; Puopolo AD; Munoz DR; Sheldon EA; Mangione A; Bohidar NR; Geba GP;
J Pain; 2003 Aug; 4(6):307-15. PubMed ID: 14622687
[TBL] [Abstract][Full Text] [Related]
17. The second generation of COX-2 inhibitors: what advantages do the newest offer?
Stichtenoth DO; Frölich JC
Drugs; 2003; 63(1):33-45. PubMed ID: 12487621
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
19. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
Leung AT; Malmstrom K; Gallacher AE; Sarembock B; Poor G; Beaulieu A; Castro R; Sanchez M; Detora LM; Ng J
Curr Med Res Opin; 2002; 18(2):49-58. PubMed ID: 12017209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
